Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Map My Mole, by Community Dermatology Limited, is a service that offers remote assessments of moles and skin lesions by consultant dermatologists.
Their missions in to bring skin checks to where the patient is, whether at home or in one…
Working in collaboration with partners across health and care, its multi-disciplinary team carries out health technology assessments of health or care technologies that are not a medicine and publishes national guidance on their use in Wales.
Read more here.
Attendees
Sponsors and
Exhibitors
Webinars
Contact us